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ABSTRACT: Migraines are a type of headache that specifically act on only one side of the head, although about 30%
of patients with migraines may experience a bilateral headache. Migraines are brain disorders that typically involve
issues of sensory processing taking place in the brainstem. Possible causation has been linked to blood vessels, blood
flow, and oxygen levels in the brain. Migraines can be described in three phases, all of which have a common
neuropeptide known as the calcitonin gene related peptide (CGRP). CGRP increases in plasma have been linked to
migraine headaches, and specific treatment plans have been tailored to account for this. CGRP is a vasodilator that
causes dilation of cranial blood vessels and can lead to possible neurogenic inflammation in the periphery of its release
while activating the pain pathway in the brainstem. The primary treatment for migraines is currently drugs from the
triptan family and NSAIDs, as well as prophylactic drugs including antiepileptic drugs, beta-blockers, and Ca2+
channel blockers. This literature review will expand on this information regarding migraines, specifically discussing the
pathophysiology, treatment, and CGRP relation to migraines through a summary of the compilation of various studies
conducted. Through this literature review, it will then become apparent as to what research should be conducted to
further the field of study on migraines based on what related topics have not been currently explored in depth in other
studies.
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INTRODUCTION
In general, migraines are a specific type of headache
that involve a unilateral pulsing pain. This pain typically
affects only one side of the head, although about 30% of
patients may experience a bilateral headache1. Migraines
have been found to last from four to 72 hours. Common
symptoms associated with this pain include nausea,
disturbed vision, vomiting, photophobia (hypersensitivity
to light), and phonophobia (hypersensitivity to sound)1.
Migraines are split into two different classes: the
common and classic migraine. The majority of migraines
are classified as common migraine. In addition, migraines
can be described as having or lacking aura, which
are neurological disturbances that are visual, motor,
and sensory2. Common migraines are not typically
accompanied with aura. The classic migraine comprises
around 15% of total migraines and is thus the minority
class of migraines1.
Migraines are typically caused by issues in the cerebral
blood vessel walls, impairment in blood flow (that
could be due to severe vessel contraction), abnormal
platelet numbers, varying brain oxygenation, or varying
metabolism levels2. Migraines can be caused in response
to a single or combined effect of all of these issues,
and vary depending on the specific case of migraine
displayed and on the individual displaying it. However,
in most cases, migraines have been found to involve
blood vessels, either intracranial or extracranial, as well
as information communicated by the sensory nerve
fibers to the central nervous system2. Studies conducted
through positron emission tomography (PET) have
indicated that the activation of the brainstem and brain
is involved in initiating migraines and that this activation
is constant both with and without aura3. In this literature
review, information from a variety of studies will be
analyzed and discussed regarding the pathophysiology,
treatment, and CGRP effects of migraines. Afterwards,
these experiments will be summarized to discuss future
research that should take place to make further progress
in this field.
CALCITONIN GENE RELATED PEPTIDE
CGRP is an important 37 amino acid neuropeptide
that was discovered using RNA transcripts26. These
transcripts are from the calcitonin gene and alternative
processing leads to different mRNAs that encode the
hormone calcitonin27. CGRP plays an important role
in the primary sensory neurons in which it is localized,
https://stars.library.ucf.edu/urj/vol9/iss1/5
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specifically through the activation of the trigeminal
system29. Its associated areas of action have a wide
distribution from the peripheral skin, cornea, respiratory,
and urogenital systems to the terminals close to smooth
muscle. CGRP-containing neurons and fibers are also
found in autonomic ganglia and in parts of the central
nervous system and in the cerebral dura29.
Activation of the trigeminal system as well as tissue
stimulation and/or tissue injury causes the release of
CGRP from the brainstem trigeminal nucleus and spinal
cord. Cranial vasodilation, coupled with the activation
and sensitization of sensory nerves, has been suggested
by several studies to lead to the headache phase29.
CGRP is a vasodilator of the cranial vessels that causes
the nerve endings to be disturbed and the nerves to be
pinched. This, in turn, causes more vasoactive material
to be released, such as CGRP, producing a vicious
cycle and resulting in neurogenic inflammation. The
method of action has been found to be related to CGRP
blocking the release of aldosterone secretion as well as
promoting the release of catecholamine, which is done
through CGRP Type 1 receptors. This action leads to the
vasodilation effect that is associated with CGRP27.
CGRP has also been found to enhance the activity of
another neuropeptide, Substance P (SP), when they are
both co–administered in the CNS. This enhanced activity
has been suggested due to CGRP’s ability to inhibit an
enzyme directly involved in SP degredation29. SP has
also been linked to excitation of the neuronal network,
where CGRP is believed to control SP degradation.
Thus, CGRP release has been shown to have correlations
with the duration and intensity of painful stimuli.
CGRP receptors have been found to contain proteins
(RAMPs, or receptor activity modifying proteins) that
must be present to move the receptor to the membrane
of the cell. There are various forms of RAMP: RAMP1,
the form of RAMP that is specifically involved with
CGRP, moves the functional glycoprotein receptor to
the membrane surface to act as a receptor for CGRP30.
This glycoprotein in humans is the rate-limiting factor
for the release of CGRP in neurons31.
Previously, CGRP receptors were separated into two
CGRP receptor types, however, as of now, experiments
have confirmed that there is only one CGRP receptor,
which is the CGRP1 receptor.There are many components
of a CGRP receptor, which include a transmembrane
domain for a receptor activity modifying protein type 1
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(RAMP1), a G protein coupled receptor, and a receptor
component protein (RCP)32. All of these components
are necessary to form a working CGRP receptor. It has
been determined that the first seven amino acids on the
N-terminal end of the CGRP receptor are necessary to
lead to the activation of the receptor, and as such various
CGRP receptor antagonists are involved with this end of
the protein32.

CGRP has also been found with the brain-derived
neurotrophic factor (BDNF) in trigeminal neurons,
making BDNF a mediator of trigeminal nociceptive
plasticity26. BDNF is a neurotrophin that regulates
factors such as maintenance, differentiation, and survival
of various central and peripheral neurons. When BDNF
is in low concentrations, this can lead to excitation of
neurons in the hippocampus, cerebellum, and cortex39.

CGRP receptors can be found in many different locations
in many different types of cells, and are not just limited to
the cardiovascular and nervous system. CGRP receptors
are on glia and neurons in the central nervous system,
as well as on many second order neurons, in addition
to mast cells that are present inside the dura mater32.
Various antimigraine treatments act on CGRP release
through involvement of CGRP receptors. Nonsteroidal
Anti–Inflammatory Drugs (NSAIDs), for example,
block the release of CGRP that is promoted through
the activation of the prostaglandin receptor. By contrast,
neuronal 5HT receptors are activated by triptans, which
lead to the blockage of CGRP release33.

CGRP has also been found to increase plasma protein
leakage by various neuropeptides, including SP. The
effect of these neuropeptides has been increased by
injection of CGRP40. It has accordingly been theorized
that the co-release of CGRP with these neuropeptides
may have additive effects in pain. In addition, CGRP and
SP levels have been found to increase salivary secretions
of patients suffering from migraines26. Thus, inhibiting
the release of these neuropeptides, specifically CGRP, is
an important treatment for migraines.

Dural surface electrical stimulation has led to a release
of CGRP from trigeminal afferents. This release leads
to vasodilation and an increase of the meningeal blood
flow. Nitric oxide (NO) has a synergistic effect along
with CGRP on the blood flow, and this theory has been
proposed to explain the NO-mediated facilitation of
CGRP synthesis and release in the trigeminal ganglia
neurons34. CGRP promoter activity has been increased
by overexpression of nitric oxide synthase and NO
donors.
Nitric oxide is a vasodilator similar to CGRP that affects
the arterial diameter and increases it, which leads to an
increase in blood flow throughout the brain, causing
a similar role to CGRP in the pathomechanism of a
migraine35. In addition, NO increases the production
and exocytosis of CGRP, even when the stimulation
is electrical34. Accordingly, inhibitors of nitric oxide
synthesis prevent CGRP release37.
Sex hormones in females are also important in the
synthesis and the eventual expression of the receptor for
CGRP26. 17B-estradiol leads to increased neurogenic
vasodilation, and the mechanism through which this
takes place is possibly through an increase of CGRP.
This is believed to be a method by which 17B-estradiol
exacerbates migraines in females38.

Published by STARS, 2016

CURRENT TREATMENT OF MIGRAINE
Prophylactic treatments are used to treat acute migraine
attack, and are currently used as strategies to treat
migraine headaches. Treatment methods include such
first-line drugs as triptans and NSAIDS; in addition,
anti-epileptic drugs, antidepressants, beta-blockers, and
natural supplements are used to treat migraines (Table
1)4. Acupuncture, as well as other non-drug treatments,
is used as well.
Medications
Drugs are utilized in the asymptomatic phase between
acute attacks where no symptoms are observable while
in the prophylaxis of a migraine2. These drugs include
Timolol and Propranolol, which are both beta–blockers.
Propranolol has been found to act by inhibiting cortical
spreading depression in the aura phase of migraines, and
a possible method of action to achieve this inhibition
effect has been through the blockage of glutamate
release41. For patients with depression or sleep issues,
Amitriptyline, a tricyclic antidepressant, is used40. Drugs
such as Divalproex, an anticonvulsant, and Verapamil, a
calcium channel blocker, are also used2.
Acute attack treatment is divided into prodromal phase
and headache phase. The prodromal phase is described
by aura and neurological symptoms that are experienced
prior to the actual headache26. Treatment applied during
the prodromal phase is conducted by the Triptan family,
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which includes drugs such as Zolmitriptan, Naratriptan,
Rizatriptan, Eletriptan, Almotriptan, and Sumitriptan,
all of which have been shown to quickly decrease
migraine headaches in patients2. Sumatriptan is the
most widely used antimigraine drug, and is the most
effective antimigraine prophylactic drug. This drug brings
elevated CGRP back to normal levels and also relieves
the headache in studies that have been conducted43.
Triptan oral administration inhibits gastrointestinal
mobility and thus may not completely relieve pain, and
as such various other methods of administration such as
nasal spray or subcutaneous injection may provide more
effective treatment44.
Triptans have been found to be more effective when
administered during the headache phase rather than
during the aura phase45. In fact, the general oral
treatment of migraine attacks (as recommended by the
European Federation of Neurological Sciences) should
take place earlier during the headache phase to prevent
incorrect absorption that may take place during the
migraine46. But if a non-oral administration of triptans
is being given, the most effective period to administer the
drugs has been found to be just prior to the symptoms of
the migraine becoming severe48. A side effect of triptan
drugs, however, is that they constrict coronary arteries,
leading to chest tightness and pain, which can in turn
create significant side effects in patients suffering from
coronary diseases49.
Another drug given during the prodromal phase is the
vasoconstrictor Dihydroergotamine, a derivative of
ergotamine. This drug should not be used while pregnant
or by patients that have coronary artery disease because
nausea is a side effect. These triptan drugs have been
shown to be effective in most cases50.
The headache phase is associated with cerebral
vasodilation as well as symptoms that include nausea
or vomiting, and analgesics such as non-steroid antiinflammatory drugs (NSAIDs) are used for treatment26.
These symptoms are not specific and act on many
different receptors and molecules such as cyclooxygenase
and other inflammation-related receptors. Naproxen,
meclogenamate, and aspirin are common NSAIDs
used for antimigraine treatment50. If the pain is severe,
opioids, mepreidine, or codeine sulphate can be used to
decrease pain. Opiates specifically decrease the calcium
influx (pre–synaptic) and increase the potassium efflux
(post–synaptic), which then decreases the duration of
the action potential by decreasing the positive charge
https://stars.library.ucf.edu/urj/vol9/iss1/5
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inside the postsynaptic terminal. Anti–emetic drugs are
used to treat nausea, examples of which are domperidone
and metoclopramide51. Medication overuse is lower in
patients that are using triptan rather than analgesics, and
opioids have been shown to have a lower efficiency at
treating migraines overall52.
Epilepsy and migraines have similar clinical features,
and as such antiepileptic drugs can also be used for
antimigraine treatment due to their prevention of the
stimulation of the brainstem4. Topiramate, gabapentin,
and valproate are involved with gamma-aminobutyric
acid by increasing the inhibition of GABA. Gabapentin
and valproate alter GABA metabolism, leading to its
eventual inhibition53. Topiramate also inhibits the
action of GABA, but does so by acting on the receptors.
In various double–blind trials, the actions of these
drugs have been shown to be more positive than a
placebo54. Topiramate has also been shown to prevent
the exocytosis of CGRP and thus prevent vasodilation
as well by directly acting on trigeminal sensory nerves55.
For a severe migraine attack, the first drugs of choice
are umatriptan administered subcutaneously and
acetylsalicylic acid administered intravenously. Steroids
can help treat a status migrainosus. Betablockers,
topiramate, valproic acid, and flunarizine are the first
choice to treat the prophylaxis of migraines. Second
choice drugs are bisoprolol, naproxen, petasites, and
amitriptyline51.
CONCLUSION
Considering all that has been analyzed in terms of
migraines and the relation to CGRP in various studies that
have been conducted, it is the author’s recommendation
that additional CGRP receptor antagonists that are able
to decrease the release of CGRP are the most promising
avenue, and thus should receive particular attention. This
experiment can effectively be conducted through analysis
of CGRP effects under typical conditions, analysis of
known CGRP receptor antagonists, and analysis of
new CGRP receptor antagonists, an area where current
research is lacking. In an ideal situation, this experiment
would be conducted on ex-vivo dura mater from an
animal such as a mouse.
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Table 1. Common Medications for Anti–Migraine Treatment4
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